Pre-treatment De Ritis ratio serves as a potential prognostic biomarker in renal cell carcinoma: a systematic review and meta-analysis

CURRENT STATUS: UNDER REVIEW

Cancer Cell International  ·  BMC

Jinze Li
North Sichuan Medical University

Lei Peng
North Sichuan Medical University

Jinming Li
North Sichuan Medical University

Bo Cheng
North Sichuan Medical University

Haocheng Gou
North Sichuan Medical University

Yunxiang Li
North Sichuan Medical University

liyunxiang369@126.com Corresponding Author
ORCiD: 0000-0002-4019-7843

DOI:
10.21203/rs.3.rs-16963/v1

SUBJECT AREAS
Cancer Biology

KEYWORDS
De Ritis ratio, Renal cell carcinoma, Prognosis, Systematic review, Meta-analysis
Abstract

Background Previous studies have evaluated the associations of aspartate transaminase to alanine transaminase (De Ritis) ratio with clinical outcome of renal cell carcinoma (RCC), but the findings are inconsistent. We therefore performed this meta-analysis to explore the prognostic value of the pre-treatment De Ritis ratio in patients with RCC.

Methods PubMed, EMBASE, Science and Cochrane Library were searched systematically to identify all eligible studies as of February 2020. The hazard ratio (HR) with 95% confidence interval (CI) were extracted to evaluate their correlation.

Results A total of 5,025 patients from 8 studies were included in the meta-analysis. Patients with an increased pre-treatment De Ritis ratio had worse overall survival (HR = 1.52, 95% CI 1.27 to 1.82, P < 0.001), cancer-specific survival (HR = 1.81, 95% CI 1.47 to 2.23, P < 0.001), progression-free survival (HR = 1.24, 95% CI 1.05 to 1.47, P = 0.011), and metastasis-free survival (HR = 1.61, 95% CI 1.25 to 2.07, P < 0.001). Subgroup analysis according to disease stage and cut-off value revealed that De Ritis ratio had a significant prognostic value for OS and PFS in all subgroups.

Conclusion The available evidence suggests that an increased De Ritis ratio was significantly correlated with worse survival in patients with RCC. Pre-treatment De Ritis ratio may serve as a potential prognostic biomarker in patients with RCC, but further studies are warranted to support these results.

Background

Renal cell carcinoma (RCC) is a common malignant tumor in adults and has an increasing incidence in the past two decades[1]. In 2020, approximately 73,750 new RCC cases and 14,830 deaths predicted in the United States[2]. Despite an increase in early detection of RCC, nearly 20% of patients already have local progression or metastasis disease at the
time of initial diagnosis[3]. Moreover, postoperative cancer recurrence occurs in 20%-40% of patients with localized RCC[4]. Thus, it is of great value to define the prognostic indicators of survival, metastasis or recurrence in patients with RCC.

Tumor, node and metastasis (TNM) staging is an important traditional prognostic factor for RCC, with limited accuracy when used alone[5]. Numerous clinical prognostic or predictive factors have been identified based on clinical trials and retrospective univariate or multivariate analysis, including performance status, appearing symptoms, and paraneoplastic syndromes[6]. Besides, laboratory values are also used for prognosis, such as serum protein, corrected calcium, erythrocyte sedimentation rate, and neutrophil to lymphocyte ratio[7, 8].

Aspartate transaminase (AST) and alanine transaminase (ALT) are the most important transaminase in the body, reflecting hepatocellular damage[9]. The ratio of serum AST to ALT, i.e. De Ritis ratio, is usually used to identify the etiology of various hepatitis[10]. Recent studies confirmed De Ritis ratio as a biomarker can predict the prognosis of several tumors, such as breast cancer, gastric adenocarcinoma and nasopharyngeal cancer[11-13]. However, the prognostic value of this ratio in patients with RCC remains unclear. Bezan et al. [14] found that patients with a high De Ritis ratio had inferior overall survival (OS) and metastasis-free survival (MFS), whilst another study reported no correlation between high DR Ritis rate and OS[15]. Therefore, this study aims to explore the prognostic value of the pretreatment De Ritis ratio in patients with RCC and provide higher-level medical evidence for clinical practice.

Materials And Methods

Search strategy

This present study was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria[16]. PubMed, EMBASE, Science and Cochrane
Library were comprehensively searched to identify eligible studies up to February 2020 without the restriction of language. The search was produced using the following terms: (“aspartate transaminase” OR “AST” OR “alanine transaminase” OR “ALT” OR “aspartate transaminase/alanine transaminase ratio” OR “AST/ALT ratio” OR “AST to ALT ratio” OR “De Ritis ratio”) AND (“renal cell carcinoma” OR “renal cell cancer” OR “renal tumor” OR “kidney cancer” OR “kidney tumor”) AND (“prognostic” OR “prognosis” OR “survival” OR “outcome” OR “recurrence” OR “mortality”). A manual search of reference lists of related studies was also performed. Two authors reviewed the literature independently, any differences settled through discussion with a third author.

**Inclusion and exclusion criteria**

Qualified studies should meet the following inclusion criteria: (1) randomized controlled studies, cohort studies, or observational studies; (2) patients with RCC were histopathologically confirmed; (3) pre-treatment De Ritis ratio was obtained, (4) estimating the relationship between De Ritis ratio and RCC prognosis; (5) reported available data for analysis, including OS, cancer-specific survival (CSS), progression-free survival (PFS), and MFS. Exclude studies based on the following criteria: (1) studies involving animal; (2) reviews, comments, letters, case reports, and unpublished articles; (3) studies with unavailable data or insufficient data for analyses; (4) duplicated studies based on the same cohort.

**Data extraction and quality assessment**

Two reviewers independently extracted the required data from eligible studies, which were as follows: the first author's name, year of publication, study region, study design, tumor type, treatment, sample size, patient age, the cut-off value of De Ritis ratio, analysis method, follow-up period. Furthermore, all outcome parameters were directly extracted with hazard ratio (HR) and 95% confidence interval (CI). The main outcome was OS, while
the secondary outcomes were CSS, PFS, and MFS. When both univariate and multivariate analysis were used in the study, data from the multivariate analysis was extracted. The quality of all included studies was estimated utilizing the Newcastle-Ottawa scale (maximum score 9) described by Wells et al[17], and studies with a score of ≥ 7 were deemed high-quality. All discrepancies were discussed through negotiation or finally decided by a third reviewer.

**Statistical analyses**

The statistical analysis of this study was performed using Stata v.15.0 (Stata Corp, College Station, TX, USA). The merged HRs with 95% CIs were adopted to evaluate the correlation between pre-treatment AST / ALT ratio and prognosis. Heterogeneity between studies was estimated using Cochran’s Q and I² tests. P < 0.10 or I² > 50% represented a significant heterogeneity, and a random-effects model was chosen. Otherwise, a fixed-effects model was applied. Moreover, we performed a subgroup analysis to investigate the cause of heterogeneity. Sensitivity analysis was also performed by dropping each study individually to assess the stability of the findings. Publication bias was evaluated by using Egger’s and Begg’s tests, as the number of included studies is less than 10. Statistical significance was defined as a P value of less than 0.05.

**Results**

**Study characteristics**

Initially identified 267 articles through the search strategy, 19 studies remained after removing duplicates and excluding articles by viewing titles and abstracts. Based on corresponding inclusion and exclusion criteria, 8 articles comprising 5,025 patients were finally included in the present study[14, 15, 18-23] (Figure 1). All studies had a retrospective design, two of which were propensity score-matched analyses. 3 studies
focused on metastatic RCC[19, 21, 22], 5 studies focused on non-metastatic RCC[14, 15, 18, 20, 23]. These studies were conducted in five countries, including China, Korea, Turkey, Japan, and the United States. The median age of patients included in the study ranged from 55 to 65 years. Cut-off values for the De Ritis ratio ranged from 1.0 to 1.5. The median follow-up period for the included studies ranged from 21 to 60 months, and only one study not reported the follow-up period[22]. 7 studies recorded the connections of De Ritis ratio with OS, 5 studies recorded CSS, 2 studies recorded PFS, and only study recorded MFS[14]. All studies were regarded as high-quality based on the NOS score.

Table 1 records the basic characteristics and quality assessments of all included studies.

**Overall survival**

Seven studies including 4,782 patients recorded about OS[14, 15, 18-22]. Since moderate heterogeneity was found, the random-effects model was adopted ($I^2 = 47.5\%, P = 0.076$). The merged results demonstrated that patients with an increased pre-treatment De Ritis ratio had inferior OS (HR = 1.52, 95% CI 1.27 to 1.82, $P < 0.001$, Figure 2).

**Cancer-specific survival**

Five studies recorded the prognostic role of pre-treatment the De Ritis ratio in patients with RCC on CSS, including 3,884 patients[15, 19-21, 23]. The pooled results revealed that high pre-treatment De Ritis ratio was related to worse CSS (fixed-effects model: HR = 1.81, 95% CI 1.47 to 2.23, $P < 0.001$), and with no heterogeneity ($I^2 = 16.1\%, P = 0.312$, Figure 3A).

**Progression-free survival and metastasis-free survival**

Two studies with 3,123 patients provided the PFS data[20, 22]. The combined results presented that RCC patients with an increased De Ritis ratio had a higher risk of progression (fixed-effects model: HR = 1.24, 95% CI 1.05 to 1.47, $P = 0.011$, Figure 3B),
and without heterogeneity ($I^2 = 0.0\%, P = 0.416$). Besides, only one study reported about MFS\[14\], and patients with elevated pre-treatment De Ritis ratio was related to the increased MFS (HR = 1.61, 95% CI 1.25 to 2.07, P < 0.001).

**Subgroup analyses**

Limited to the number of studies included in the meta-analysis, we only conducted subgroup analysis for OS and CSS oncologic outcomes, and stratified by disease stage, treatment method, cut-off value, analysis method, or sample size (**Table 2**). Subgroup analysis by disease stage demonstrated that high pre-treatment De Ritis ratio was related to inferior OS (HR = 1.46, 95% CI 1.29 to 1.63, P < 0.001) and CSS (HR = 1.79, 95% CI 1.35 to 2.38, P < 0.001) in patients with metastatic RCC, and the similar results were observed in patients with non-metastatic RCC (OS: HR = 1.54, 95% CI 1.13 to 2.08, P = 0.006; CSS: HR = 1.84, 95% CI 1.36 to 2.49, P < 0.001). In terms of subgroup analysis of treatment method, the high pre-treatment De Ritis ratio in patients with RCC was an independent predictor of OS (surgery: HR = 1.60, 95% CI 1.20 to 2.13, P < 0.001; non-surgery: HR = 1.42, 95% CI 1.19 to 1.70, P < 0.001). For subgroup with cut-off value of > 1.3, the patients with higher pre-treatment De Ritis ratio had poor OS (HR = 1.82, 95% CI 1.49 to 2.20, P = 0.001) and CSS (HR = 1.84, 95% CI 1.36 to 2.49, P < 0.001). Likewise, in the cut-off value of ≤ 1.3 group, increased De Ritis ratio was correlated with worse OS (HR = 1.29, 95% CI 1.11 to 1.49, P < 0.001) and CSS outcomes (HR = 1.79, 95% CI 1.35 to 2.38, P < 0.001). High pre-treatment De Ritis ratio was found to be independent prognostic factor for OS in the analysis method subgroup analyses (multivariate: HR = 1.71, 95% CI 1.43 to 2.06, P < 0.001; univariate: HR = 1.34, 95% CI 1.27 to 1.82, P = 0.002). Additionally, stratified by sample size, the higher pre-treatment De Ritis ratio had steep inferior OS (HR = 1.69, 95% CI 1.40 to 2.04, P < 0.001) and CSS (HR = 1.74, 95% CI 1.31 to 2.30, P < 0.001) in the sample size > 300 subgroup, which was consistent with the
results of the sample size \( \leq 300 \) subgroup (OS: HR = 1.43, 95% CI 1.27 to 1.82, \( P = 0.015 \); CSS: HR = 1.91, 95% CI 1.40 to 2.60, \( P < 0.001 \)).

**Sensitivity analysis and publication bias**

Restricted to the number of articles included in the study, we performed sensitivity analysis for OS and CSS outcomes only. After removing each study one by one, no significant change in the pooled HR was observed, which undoubtedly proved the reliability of our results (Figure 4). Also, Egger’s and Begg’s tests were applied to estimate the publication bias. Based on the Egger’s test (OS: \( P = 0.084 \), CSS: \( P = 0.279 \)) and Begg’s test (OS: \( P = 0.368 \), CSS: \( P = 0.462 \)) results, there was no significant evidence of publication bias.

**Discussion**

RCC is one of the most common solid lesions in the kidney, accounting for about 80%-90% of all renal malignancies[1]. The prognosis of RCC is affected by a variety of factors, including patient age, clinical manifestations, laboratory values, and tumor pathologic variables such as pathological stage, nuclear grade, and histological subtype[6, 24]. Tumor stage and grade are considered as common prognostic markers for RCC, but the application of these factors in clinical practice remains problematic[25]. How to more accurately identify those patients with poor prognosis before treatment, and carry out the risk stratification of tumors are of great significance for the choice of treatment options and the guidance of postoperative follow-up. Therefore, finding potential prognostic markers for RCC prognosis has become a hot spot in clinical research.

Serum De Ritis ratio was originally adopted to evaluate the prognosis of various liver diseases, including viral hepatitis, alcoholic hepatitis, and fatty liver[10]. Due to laboratory tests are routinely performed before treating cancer patients, De Ritis ratio can be a simple, convenient, and inexpensive measurement method. Previous studies have
reported De Ritis ratio was significantly associated with the prognosis of several tumors, including RCC[11-14]. However, the true prognostic value of this ratio in patients with RCC remains controversial.

For all we know, this is the first meta-analysis to appraise the prognostic value of pre-treatment De Ritis ratio in patients with RCC. The study revealed that patients with higher pre-treatment De Ritis ratio had worse survival outcomes regarding OS, CSS, PFS, and MFS. Subgroup analyses of OS and CSS by disease stage, treatment method, cut-off value, analysis method, or sample size obtained similar results. We also performed sensitivity analyses to explore potential sources of heterogeneity, and no significant change was observed. There was no significant evidence of publication bias. Thus, the meta-analysis indicates that pre-treatment De Ritis ratio is an important prognostic predictor for the survival of RCC patients.

ALT and AST are common blood tests for liver disease and can reflect hepatocellular damage or death. ALT is mainly present in the liver, while AST is widely distributed in various tissues such as the heart, liver, brain, muscle, and kidney tissues[10]. Hence, ALT suggests liver disease specifically, whilst AST may be associated with several diseases that affect other organs. Pathological processes that have been proved to cause tissue damage, high proliferative states and faster tumor cell turnover tend to enhance serum AST level rather than ALT level, making the De Ritis (AST/ALT) ratio an attractive potential clinical biomarker[26].

Although the De Ritis ratio is a promising marker, the specific mechanism of higher this ratio and inferior prognosis of cancer patients remains unclear. Indeed, cancer cells have a higher rate of glycolysis compared with normal cells, even in the presence of oxygen, and abnormal glycolytic metabolism produces sufficient ATP to promote cancer cell proliferation, this phenomenon is known as the “Warburg effect”[27, 28]. Increased
glycolysis in tumor cells is thought to be related to changes in nicotinamide adenine dinucleotide (NAD)-related enzymes and glucose transporters within mitochondria, according to Dorward et al[29]. Higher lactate dehydrogenase and cytosolic (NADH)/NAD + ratio play an important role in maintaining enhanced glycolysis[30]. It must be highlighted that AST is a pivotal component of the malate-aspartate shuttle in the glycolysis pathway that relocates NADH into mitochondria[10]. Moreover, the previous study had confirmed von Hippel-Lindau (VHL) significantly associated with renal clear-cell type RCC was presented in the cytoplasm of mitochondria[31]. The loss of VHL and an increase in hypoxia-inducible factor expression influence several metabolic pathways, including glycolysis and oxidative phosphorylation[32]. Accordingly, AST is most probably involved in the glycolysis mechanism of clear-cell type RCC with VHL loss[20]. However, further investigation is needed to explore the exact mechanism. As a promising biomarker, De Ritis ratio has significant implications for clinical practice. Our meta-analysis affirms that patients with an increased pre-treatment De Ritis ratio had worse survival outcomes. It could be a potential selection criterion for the hierarchical management of risk factors for RCC and adjuvant therapies[14]. Given that a prognostic factor must be verified in well-designed, large-scale with an independent cohort before it can be applied universally, the findings should be interpreted cautiously.

Despite the study provides stronger evidence for the prognostic value of the pre-treatment De Ritis ratio in patients with RCC, there are certain limitations. Firstly, only 8 studies involving 5,025 patients were included in the meta-analysis, which is a relatively small sample size and may lead to a biased conclusion. Secondly, all included studies were retrospective, which may have an inherent structural bias, and the duration of follow-up was relatively short. Thirdly, although the included studies attempted to exclude all patients with liver disease, there were still undetected liver pathological conditions
that could affect the serum AST or ALT levels and distort the De Ritis ratio.

Conclusion

The available evidence suggests that patients with an increased pre-treatment De Ritis ratio had worse OS, CSS, PFS, and MFS, indicating that this ratio may serve as a potential prognostic biomarker in patients with RCC. However, prospective, well-designed, and large-scale studies are warranted to validate our findings.

Abbreviations

RCC: Renal cell carcinoma; AST: Aspartate transaminase; ALT: Alanine transaminase; OS: Overall survival; CSS: Cancer-specific survival; PFS: Progression-free survival; MFS: Metastasis-free survival; NOS: Newcastle-Ottawa scale; HR: Hazard ratio; CI: Confidence interval; VHL: Von Hippel-Lindau.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

All the data (pooled HR with 95% CI of OS, CSS, PFS, RFS, and MFS) used to support the findings of this study are included within the article.

Competing interests

The authors declare that they have no competing interests.

Funding

This article was funded by the special project of Nanchong City School Cooperation (Grant Number: NSMC20170457). The corresponding author had full access to all the data in the
study and had final responsibility for the decision to submit for publication article.

Authors’ contributions

Protocol/project development: YXL and JZL; Data collection or management: JZL, LP and JML; Data analysis: JZL, BC and HCG; Manuscript writing/editing: JZL, LP. All authors read and approved the final manuscript.

Acknowledgments

The authors thank Ms Mengqi Chen for providing continuous encouragement to Dr Jin Ze Li to pursue his career in medicine.

References

1. Ljungberg B, Albuges L, Abu-Ghanem Y, Bensalah K, Babestani S, Fernandez-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol. 2019;75(5):799-810.

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.

3. Brufau BP, Cerqueda CS, Villalba LB, Izquierdo RS, Gonzalez BM, Molina CN. Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT. Radiographics: a review publication of the Radiological Society of North America, Inc. 2013;33(6):1691-1716.

4. Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer journal (Sudbury, Mass). 2008;14(5):288-301.

5. Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, Pantuck AJ, Zigeuner R, Karakiewicz PI. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol. 2011;60(4):644-661.

6. Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal
cell carcinoma: a literature review. World journal of urology. 2018;36(12):1943-1952.

7. Ohno Y. Role of systemic inflammatory response markers in urological malignancy. Int J Urol. 2019;26(1):31-47.

8. Sekar RR, Patil D, Baum Y, Pearl J, Bausum A, Bilen MA, Kucuk O, Harris WB, Carthon BC, Alemozaffar M et al. A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma. Asian J Urol. 2017;4(4):230-238.

9. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008;245(3):194-205.

10. Botros M, Sikaris KA. The de ritis ratio: the test of time. The Clinical biochemist Reviews. 2013;34(3):117-130.

11. Thornburg JM, Nelson KK, Clem BF, Lane AN, Arumugam S, Simmons A, Eaton JW, Telang S, Chesney J. Targeting aspartate aminotransferase in breast cancer. Breast cancer research : BCR. 2008;10(5):R84.

12. Chen SL, Li JP, Li LF, Zeng T, He X. Elevated Preoperative Serum Alanine Aminotransferase/Aspartate Aminotransferase (ALT/AST) Ratio Is Associated with Better Prognosis in Patients Undergoing Curative Treatment for Gastric Adenocarcinoma. International journal of molecular sciences. 2016;17(6).

13. Wu J, Li S, Wang Y, Hu L. Pretreatment Aspartate Aminotransferase-to-Alanine Aminotransferase (De Ritis) Ratio Predicts the Prognosis of Nonmetastatic Nasopharyngeal Carcinoma. OncoTargets and therapy. 2019;12:10077-10087.

14. Bezan A, Mrsic E, Krieger D, Stojakovic T, Pummer K, Zigeuner R, Hutterer GC, Pichler M. The Preoperative AST/ALT (De Ritis) Ratio Represents a Poor Prognostic Factor in a Cohort of Patients with Nonmetastatic Renal Cell Carcinoma. J Urol. 2015;194(1):30-35.
15. Canat L, Ataly HA, Agalarov S, Alkan İ, Alturende F. The effect of AST/ALT (De Ritis) ratio on survival and its relation to tumor histopathological variables in patients with localized renal cell carcinoma. International braz j urol. 2018;44(2):288-295.

16. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical research ed). 2009;339:b2535.

17. Wells GA, Shea B, O'Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2009. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 24 Feb 2020.

18. Gu L, Wang Z, Chen L, Ma X, Li H, Nie W, Peng C, Li X, Gao Y, Zhang X. A proposal of post-operative nomogram for overall survival in patients with renal cell carcinoma and venous tumor thrombus. J Surg Oncol. 2017;115(7):905-912.

19. Ishihara H, Kondo T, Yoshida K, Omae K, Takagi T, Iizuka J, Tanabe K. Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study. Clin Genitourin Cancer. 2017;15(5):598-604.

20. Lee H, Lee SE, Byun SS, Kim HH, Kwak C, Hong SK. De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study. BJU Int. 2017;119(2):261-267.

21. Kang M, Yu J, Sung HH, Jeon HG, Jeong BC, Park SH, Jeon SS, Lee HM, Choi HY, Seo SI. Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for
metastatic renal cell carcinoma. Int J Urol. 2018;25(6):596-603.

22. Kim SH, Park EY, Joo J, Chung J. The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma. J Oncol. 2018;2018:1953571.

23. Ikeda T, Ishihara H, Takagi T, Fukuda H, Yoshida K, Izuka J, Kobayashi H, Okumi M, Ishida H, Kondo T et al. The De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Prognosticator in Patients With End-stage Renal Disease-associated Renal Cell Carcinoma. Clin Genitourin Cancer. 2019.

24. Lane BR, Kattan MW. Prognostic models and algorithms in renal cell carcinoma. The Urologic clinics of North America. 2008;35(4):613-625; vii.

25. Delahunt B. Advances and controversies in grading and staging of renal cell carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2009;22 Suppl 2:S24-36.

26. Conde VR, Oliveira PF, Nunes AR, Rocha CS, Ramalhosa E, Pereira JA, Alves MG, Silva BM. The progression from a lower to a higher invasive stage of bladder cancer is associated with severe alterations in glucose and pyruvate metabolism. Experimental cell research. 2015;335(1):91-98.

27. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nature reviews Cancer. 2011;11(5):325-337.

28. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annual review of cell and developmental biology. 2011;27:441-464.

29. Dorward A, Sweet S, Moorehead R, Singh G. Mitochondrial contributions to cancer cell physiology: redox balance, cell cycle, and drug resistance. Journal of bioenergetics and biomembranes. 1997;29(4):385-392.
30. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer cell. 2006;9(6):425-434.

31. Shiao YH, Resau JH, Nagashima K, Anderson LM, Ramakrishna G. The von Hippel-Lindau tumor suppressor targets to mitochondria. Cancer research. 2000;60(11):2816-2819.

32. Sudarshan S, Karam JA, Brugarolas J, Thompson RH, Uzzo R, Rini B, Margulis V, Patard JJ, Escudier B, Linehan WM. Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol. 2013;63(2):244-251.

Tables

Table 1. Baseline characteristics of include studies and methodological assessment.

TKI tyrosine kinase inhibitor, TT targeted therapy, AST aspartate transaminase, ALT alanine transaminase, OS overall survival, CSS cancer-specific survival, PFS progression-free survival, MFS metastasis-free survival, NR not report.

Table 2. Subgroup analyses of OS and CSS.
| Authors (year) | Country  | Study design          | Tumor type        | Treatment | Number of patients | Age (yr) |
|---------------|----------|-----------------------|-------------------|-----------|--------------------|----------|
| Bezan 2015    | America  | Retrospective         | Non-metastatic    | Surgery   | 698                | Med: 65.4 (55.8-73.4) |
| Canat 2017    | Turkey   | Retrospective         | Non-metastatic    | Surgery   | 298                | Med: 61 (22-86)       |
| Gu 2017       | China    | Retrospective         | Non-metastatic    | Surgery   | 185                | M 56.1   |
| Ishihara 2017 | Japan    | Propensity score matching | Metastatic        | Surgery   | 118                | Med      |
| Lee 2017      | Korea    | Propensity score matching | Non-metastatic    | Surgery   | 2965               | Med: 54 (47-65)       |
| Kang 2018     | Korea    | Retrospective         | Metastatic        | TKI       | 360                | Med: 54 (51-67)       |
| Kim 2018      | Korea    | Retrospective         | Metastatic        | TT        | 158                | M 58.6   |
| Ikeda 2019    | Japan    | Retrospective         | Non-metastatic    | Surgery   | 243                | Med: 54 (51-67)       |
| Outcome | Variable                | No. of studies | Model       | HR (95% CI) |
|---------|-------------------------|----------------|-------------|-------------|
| OS      | All                     | 7              | Random      | 1.52 (1     |
|         | Disease stage           |                |             |             |
|         | Metastatic              | 3              | Fixed       | 1.46 (1     |
|         | Non-metastatic          | 4              | Random      | 1.54 (1     |
|         | Primary treatment       |                |             |             |
|         | Surgery                 | 5              | Random      | 1.60 (1     |
|         | Non-surgery             | 2              | Fixed       | 1.42 (1     |
|         | Cut-off value           |                |             |             |
|         | > 1.3                   | 4              | Fixed       | 1.82 (1     |
|         | ≤ 1.3                   | 3              | Fixed       | 1.29 (1     |
|         | Analysis method         |                |             |             |
|         | Multivariate            | 4              | Fixed       | 1.72 (1     |
|         | Univariate              | 3              | Random      | 1.34 (1     |
|         | Sample size             |                |             |             |
|         | > 300                   | 3              | Fixed       | 1.69 (1     |
|         | ≤ 300                   | 4              | Random      | 1.43 (1     |
| CSS     | All                     | 5              | Fixed       | 1.81 (1     |
|         | Disease stage           |                |             |             |
|         | Metastatic              | 2              | Fixed       | 1.79 (1     |
|         | Non-metastatic          | 3              | Fixed       | 1.84 (1     |
|         | Cut-off value           |                |             |             |
|         | > 1.3                   | 3              | Fixed       | 1.84 (1     |
|         | ≤ 1.3                   | 2              | Fixed       | 1.79 (1     |
|         | Sample size             |                |             |             |
|         | > 300                   | 2              | Fixed       | 1.74 (1     |
|         | ≤ 300                   | 3              | Random      | 1.91 (1     |

*OS* overall survival, *CSS* cancer-specific survival, *HR* hazard ratio, *CI* confidence interval.

**Figures**
Figure 1

Flow diagram of studies identified, included and excluded.
### Table

| ID | HR (95% CI) | Weight |
|----|-------------|--------|
| Bezav 2015 | 1.76 (1.34, 2.32) | 18.70 |
| Canat 2017 | 1.10 (0.85, 1.42) | 19.78 |
| Gu 2017 | 2.49 (1.22, 5.08) | 5.32 |
| Ishihara 2017 | 2.30 (1.10, 5.08) | 4.72 |
| Lee 2017 | 1.56 (1.07, 2.27) | 13.51 |
| Kang 2018 | 1.69 (1.19, 2.39) | 14.74 |
| Kim 2018 | 1.34 (1.09, 1.64) | 23.22 |
| Overall (I-squared = 47.5%, p = 0.076) | 1.52 (1.27, 1.82) | 100.00 |

**NOTE:** Weights are from random effects analysis

### Figure 2

**Forest plots of the association between De Ritis ratio and overall survival.**
**Figure 3**

Forest plots of the association between De Ritis ratio and (A) cancer-specific survival; (B) progression-free survival.
Sensitivity analysis for (A) overall survival; (B) cancer-specific survival.
### Figure 5

**Supplementary Files**

This is a list of supplementary files associated with the primary manuscript. Click to download.

- PRISMA statement.DOC